FDA expands use of Amgen's blockbuster drug

(Reuters) - Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

ConclusionAfter internal fixation of long bones with MM, full hardware coverage with the RT field could reduce the risk, though small, of disease developing in the future in the proximate hardware. Postoperative RT doses of 20 to 25 Gy in 8 to 10 fractions can achieve excellent local control.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
de Mel Multiple myeloma (MM) is an incurable plasma cell malignancy for which novel treatment options are required. Signal Transducer and Activator of Transcription 3 (STAT3) overexpression in MM appears to be mediated by a variety of factors including interleukin-6 signaling and downregulation of Src homology phosphatase-1 (SHP-1). STAT3 overexpression in MM is associated with an adverse prognosis and may play a role in microenvironment-dependent treatment resistance. In addition to its pro-proliferative role, STAT3 upregulates anti-apoptotic proteins and leads to microRNA dysregulation in MM. Phosphatase of regenera...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 23 May 2019Source: Diagnostic and Interventional ImagingAuthor(s): Alexis Danner, Eléonore Brumpt, Mona Alilet, Grégory Tio, Patrick Omoumi, Sébastien AubryAbstractPurposeThe purpose of this study was twofold. First, to compare the contrast between spinal multiple myeloma (MM) focal lesions and surrounding bone marrow obtained on T2-weighted Dixon fat-only MR images to that obtained on T1-weighted spin-echo images. Second, to search for correlation between bone marrow fat fraction assessed by T2-weighted Dixon sequence and International Myeloma Working Group myeloma d...
Source: Diagnostic and Interventional Imaging - Category: Radiology Source Type: research
Publication date: Available online 29 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yaohua Cao, Ning Wan, Zhuoru Liang, Jingmei Xie, Sen Wang, Tengfei Lin, Tiantian Zhang, Jie JiangAbstractMany new regimens have been applied to newly diagnosed transplant-ineligible multiple myeloma, but no head-to-head research has been performed to compare the efficacy of these treatments. Currently lenalidomide plus dexamethasone (Rd) is one of the standard treatments. Our aim was to make a comparison of these treatments to Rd by a network meta-analysis. We performed a systematic review and network meta-analysis. We ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conditions:   Irradiated Bone Marrow;   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Multiple Myeloma;   Graft Vs Host Disease Interventions:   Drug: Conditioning treatment  " Treosulfan-TMI " ;   Procedure: SCT;   Drug: GvHD prophylaxis Sponsor:   IRCCS San Raffaele Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractPurpose of ReviewGiven the median age at diagnosis of 69, multiple myeloma (MM) is commonly identified among elderly individuals. Over-treatment of the frail may lead to unnecessary morbidity, while under-treatment of fit elderly patients may prevent improvement in organ function; both instances reducing quality of life. Here, we summarize assessments of frailty and include considerations in managing newly diagnosed elderly MM patients.Recent FindingsEligibility criteria for studies of anti-myeloma agents have traditionally relied on performance status and comorbidities; however, geriatric and myeloma-specific frai...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
Effects of miR‑181a on the biological function of multiple myeloma. Oncol Rep. 2019 May 15;: Authors: Liu N, Yang J, Yuan R, Peng J, Liu L, Guo X Abstract The present study aimed to investigate the role of miR‑181a in multiple myeloma (MM) cell lines. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to detect the expression of microRNA (miR)‑181a. The MM cell line RPMI 8226 stably transduced with miR‑181a mimics or inhibitor was established via lentiviral vectors. A Cell Counting Kit‑8 proliferation assay, flow cytometry and a Transwell assay were conducted ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Conclusion18F-FDG PET/CT showed excellent detection rate in nodal and splenic disease—a rate better than CT. For BM and GI evaluation, in order to reach good accuracy, the selection of patients and the use of specific criteria for evaluation of these organs seems to be crucial. Moreover, PET/CT altered the management and therapeutic approach in about 20% of patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Sarita Rani Jaiswal, Prakash Bhakuni, Satish Bansal, Hema Malini Aiyer, Sneh Bhargava, Suparno ChakrabartiGraphical abstract
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Condition:   Leukemia, Lymphoma, Multiple Myeloma Intervention:   Behavioral: coping skills training Sponsor:   Duke University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Food and Drug Administration (FDA) | Health | Myeloma | Xgeva